Physician
Hematology
Dr. Michael Millenson, MD
|
|
Give Review
Michael Millenson, MD practices Hematology. He attended Temple University School of Medicine. He received 5 awards: "America's Top Doctors", "Philadelphia Magazine", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer" and "Fellow (FACP)". Michael Millenson is a published doctor and has 47 publications published. The lastest was: 'Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Cent...' He is registered with Medicare.
Publications
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
- Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-hodgkin Lymphoma: a multicentre phase II study.
- Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.
- Copy neutral loss of heterozygosity in 20q in chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Transformed non-Hodgkin lymphoma in the rituximab era: Analysis of the NCCN outcomes database.
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-Cell lymphoma treated in the rituximab era.
- Acute Myeloid Leukemia, Version 2.2013.
- Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive Analysis from the NCCN lymphoma outcomes project.
- Low NK Cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma.
- Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular Lymphoma and its impact on initial treatment st...
- Venous thromboembolic Disease.
- Acute myeloid leukemia.
- NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic Syndromes.
- Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
- Promising survival in patients with recurrent non-small cell lung Cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
- Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic Leukemia and indolent (non-Hodgkin's) lymphoma.
- Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions.
- Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast Carcinoma patients age 40 years and older.
- Temozolomide in non-small-cell lung Cancer: preliminary results of a phase II trial in previously treated patients.
- NCCN Clinical Practice Guidelines in Oncology: myelodysplastic Syndromes.
- Cancer- and chemotherapy-induced anemia.
- Cancer- and treatment-related anemia.
- NCCN Practice Guidelines for Acute Myelogenous Leukemia.
- Myelodysplastic Syndromes.
- Myelodysplastic Syndromes clinical practice guidelines in oncology.
- A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage.
- Acute myeloid leukemia clinical practice guidelines in oncology.
- Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin Lymphoma.
- Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small Cell lung carcinoma (NSCLC).
- Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung Cancer: a phase II study of the Fox Chase Cancer Cent...
- Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung Cancer: a phase II study by the Fox Chase Cancer Center Network.
- Cutaneous B-Cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
- Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung Cancer (NSCLC): results of OPN-017.
- A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung Cancer.
- Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin Lymphoma.
- Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic System in patients with atrial fibrillation. BAATAF Investigators.
- Monitoring "mini-intensity" antiCoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levels.
- Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small Cell carcinom...
- Venous thromboembolic Disease. Clinical practice guidelines in oncology.
- Venous thromboembolic Disease. NCCN. Clinical practice guidelines in oncology.
- Pediatric nodal marginal zone Lymphoma may develop in the adult population.
- Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-Cell support as front-line therapy.
- Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem Cells.
- Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin''s Lymphoma.
- Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small Cell lung carcinoma.
Schools
Temple University School Of Medicine
Temple University Hospital
Beth Israel Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Fellow (FACP)
Education
-
Beth Israel Deaconess Medical Center -
Temple University Hospital -
Temple University School of Medicine
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital -
Temple University Hospital
Drug Facts
| NPI NUMBER | 1871514224 | |
| NPPES Provider LastName | MILLENSON | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 191112434 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 532.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871514224 |
| Last Name Of The Provider | MILLENSON |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Alex W. Chu, MD |
|
|
Dr. Hayley M. Knollman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saar I. Gill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph N. Tropea, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Farzana Sayani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph J. Vadakara, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anjali Avadhani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Neal Flomenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noelle V. Frey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James K. Mangan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth O. Hexner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Stadtmauer, MD
This Doctor is OpenDoctor Recommended.
|